tiprankstipranks
Trending News
More News >
VYNE Therapeutics: Strong Financials and Promising Clinical Developments Reinforce Buy Rating
PremiumRatingsVYNE Therapeutics: Strong Financials and Promising Clinical Developments Reinforce Buy Rating
2M ago
VYNE Therapeutics reports Q4 EPS (28c) vs (20c) last year
Premium
The Fly
VYNE Therapeutics reports Q4 EPS (28c) vs (20c) last year
2M ago
VYNE Therapeutics: Promising Pipeline and Strategic Focus Drive Buy Rating
Premium
Ratings
VYNE Therapeutics: Promising Pipeline and Strategic Focus Drive Buy Rating
2M ago
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data
PremiumThe FlyH.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data
4M ago
VYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trial
Premium
The Fly
VYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trial
4M ago
VYNE Therapeutics Sees Strong Shareholder Support for Growth
Premium
Company Announcements
VYNE Therapeutics Sees Strong Shareholder Support for Growth
5M ago
VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202
PremiumThe FlyVYNE Therapeutics announces results from Phase 1a SAD trial for VYN202
8M ago
VYNE Therapeutics sees cash runway through end of 2025
Premium
The Fly
VYNE Therapeutics sees cash runway through end of 2025
9M ago
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year
Premium
The Fly
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100